Pomerantz Law Firm Advises Ultragenyx Investors on Class Action Lawsuit and Key Deadlines

Investor Alert: Pomerantz Law Firm Class Action Against Ultragenyx Pharmaceutical Inc.

Pomerantz LLP has issued a critical reminder for investors concerning a class action lawsuit filed against Ultragenyx Pharmaceutical Inc. This alert is aimed at individuals who may have incurred losses during their investment in Ultragenyx (NASDAQ: RARE) and emphasizes important deadlines for potential claimants.

Overview of the Lawsuit

The law firm has indicated that the lawsuit revolves around allegations of securities fraud and other unlawful business practices engaged in by Ultragenyx and several of its executives. Investors affected by these practices are urged to reach out to Pomerantz for guidance and to gather information required to file their claims. In what has become a common theme in the pharmaceutical industry, this class action lawsuit highlights systemic issues related to transparency and accountability among listed companies.

Those who purchased or acquired Ultragenyx securities during the stated Class Period need to act quickly; the firm specifies that the deadline for requesting lead plaintiff status is April 6, 2026. Investors seeking more information can contact Danielle Peyton at Pomerantz via email ([email protected]) or through the firm’s toll-free number.

Contextual Background

The crux of the circumstances surrounding this lawsuit stems from significant stock price changes correlated with major announcements by Ultragenyx. On July 9, 2025, the company, alongside its development partner, Mereo BioPharma Group plc, released news indicating that the Phase 3 portion of their UX143 (setrusumab) trial was moving towards final analysis. This announcement resulted in a notable drop in Ultragenyx's stock price, which fell drastically by $10.41, representing a decline of 25.11% by the following trading day (July 10, 2025). Such volatility drew the attention of investors and regulatory bodies alike.

Following that, on December 29, 2025, Ultragenyx revealed disappointing results from both its Orbit and Cosmic Studies, stating that they failed to meet their primary endpoints. The reaction from the market was swift and harsh, with the stock losing an additional $14.47 per share (42.32%), compounding the already severe losses for investors.

Historical Significance of Pomerantz LLP

With a substantial history in corporate securities litigation, Pomerantz LLP is recognized as one of the leading firms in this arena, advocating for victims of securities fraud and corporate misconduct. Founded by the late Abraham L. Pomerantz, known as a pioneer in class action law, the firm has built a reputation for achieving multimillion-dollar settlements on behalf of its clients. Over the past 85 years, Pomerantz has upheld principles of justice and fairness in the complex world of corporate investments, ensuring that investors have a voice against corporate malpractice.

As such, Pomerantz is not only dedicated to seeking redress for affected shareholders in this case against Ultragenyx, but it also aims to set a precedent for accountability within the biotech sector, requiring corporations to uphold higher standards of integrity and transparency in their communications with shareholders.

Next Steps for Investors

Investors who believe they may be affected are strongly encouraged to take immediate action. The class action process ensures that shareholders have an opportunity to reclaim their losses and hold companies accountable for any wrongdoing. Interested parties can find more information about joining the class action lawsuit by visiting Pomerantz’s official website at www.pomerantzlaw.com.

The upcoming deadlines and procedural necessities must be observed closely to ensure that investor rights are protected in this significant legal matter. As the situation unfolds, those involved in or considering investment in Ultragenyx should stay informed and proactive in their approach to potential claims.

Pomerantz is committed to delivering effective legal representation for those who have suffered from corporate fraud. As this case progresses, it stands to serve as an essential reminder of the importance of vigilance in investment practices and corporate governance.